LATEST NEWS: 11 JUNE 2025 New findings from a trial into treating a common form of skin cancer – cutaneous squamous cell carcinoma (CSCC) – could be a game-changer for many people at high risk of recurrence of disease. Lead investigator Prof Danny Rischin presented results of primary analysis
LATEST NEWS: 10 JUNE 2025 A trial of a novel radiation therapy approach to treat advanced lung cancer is set to enrol its first participants early next year, after investigators welcomed a $1.5 million Medical Research Future Fund grant. The Primary Radiotherapy in Metastatic Lung (PRIME-Lung) study – sponsored
LATEST NEWS: 5 JUNE 2025 The Alan Walker Cancer Care Centre (AWCCC) in the Northern Territory recently recruited the 300th participant to the Australian Particle Therapy Clinical Quality Registry (ASPIRE), in a milestone achievement amid a push to expand clinical research participation in rural and remote locations. The ASPIRE
LATEST NEWS: 15 May 2025 A novel imaging modality aimed at reducing radiation therapy side effects for patients with lung cancer is set to be trialled in Australia, after researchers received a $1.86m National Health and Medical Research Council (NHMRC) grant. The NHMRC Clinical Trials and Cohort Studies Grant
LATEST NEWS: 15 April 2025 An innovative trial aimed at improving outcomes for patients with brain metastases will progress to the next stage after receiving a $120,000 grant from the Mark Hughes Foundation (MHF) Centre for Brain Research at the University of Newcastle. Congratulations to Dr Neda Haghighi from
5 March 2025: TRIAL UPDATE We’re excited to have now opened all Australian sites for the TROG 21.07 – SOCRATES HCC study, which is investigating the use of an advanced radiotherapy technique for early-stage hepatocellular carcinoma (HCC). With the opening of a clinical trial site at St George Hospital
4 March 2025: A decade on from the last participant completing treatment, the BIG 3-07/TROG 07.01 – DCIS trial is continuing to deliver valuable results. Led by TROG Cancer Research, the international, randomised phase III study aimed to improve the treatment outcomes of women diagnosed with ductal carcinoma in-situ
5 December 2024: Study shows huge improvement in progression-free survival with adjuvant rituximab containing therapy. Newly published findings of extended follow-up from a TROG Cancer Research trial of radiotherapy plus chemo-immunotherapy in follicular lymphoma (TROG 99.03 – Follicular lymphoma) provide valuable evidence in support of changing the current standard
24 October 2024: Newly published findings from the ICR-CTSU/2014/10049/TROG 14.02 RAIDER trial offer promise for the use of complex adaptive radiotherapy as an alternative to radical surgery for bladder cancer. The RAIDER team published their significant phase II trial findings in the European Urology journal in October. The trial,
18 September 2024: We’re thrilled to announce the release of globally significant results from the AGITG TOPGEAR study on which TROG collaborated, providing practice-changing evidence about preoperative chemoradiotherapy for gastric cancer. The findings, announced simultaneously at the European Society for Medical Oncology Congress in Barcelona, Spain and published in
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292
